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Abstract
Background. Epidemiological studies of adult glioma have identified genetic and environmental risk factors, 
but much remains unclear. The aim of the current study was to evaluate anthropometric, disease-related, and 
prediagnostic immune-related factors for relationship with glioma risk.
Methods. We conducted a nested case–control study among the intervention arm of the Prostate, Lung, Colorectal, and 
Ovarian Cancer (PLCO) Screening Trial. One hundred and twenty-four glioma cases were identified and each matched 
to four controls. Baseline characteristics were collected at enrollment and were evaluated for association with glioma 
status. Serum specimens were collected at yearly intervals and were analyzed for immune-related factors including 
TGF-β1, TNF-α, total IgE, and allergen-specific IgE. Immune factors were evaluated at baseline in a multivariate condi-
tional logistic regression model, along with one additional model that incorporated the latest available measurement.
Results. A family history of glioma among first-degree relatives was associated with increased glioma risk (OR = 4.41, 
P = .002). In multivariate modeling of immune factors at baseline, increased respiratory allergen-specific IgE was 
inversely associated with glioma risk (OR for allergen-specific IgE > 0.35 PAU/L: 0.59, P = .03). A logistic regression 
model that incorporated the latest available measurements found a similar association for allergen-specific IgE 
(P = .005) and showed that elevated TGF-β1 was associated with increased glioma risk (P-value for trend <.0001).
Conclusion. The results from this prospective prediagnostic study suggest that several immune-related factors are 
associated with glioma risk. The association observed for TGF-β1 when sampling closer to the time of diagnosis 
may reflect the nascent brain tumor’s feedback on immune function.
Key Points
1. This study replicated that allergen-specific IgE is inversely associated with glioma risk.
2. A family history of glioma among first-degree relatives is associated with glioma.
3. TGF-β1 became associated with glioma closer towards diagnosis.
Immune factors preceding diagnosis of glioma: a 
Prostate Lung Colorectal Ovarian Cancer Screening 
Trial nested case–control study
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Over recent decades, substantial progress has been made 
with regard to the understanding of glioma epidemiology.1 
A long-established risk factor for glioma is a history of ex-
posure to ionizing radiation.1,2 Several recent studies have 
identified common germline genetic variants that are asso-
ciated with increased risk.3 Various other factors including 
family history and allergy or atopy have also been consist-
ently associated with glioma risk.4–8
Apart from the question of glioma risk factors, another 
relevant question remains whether certain factors may 
reflect an underlying disease process before glioma di-
agnosis. Although the lifetime history of immune-related 
diseases such as allergy and autoimmunity seems to 
influence gliomagenesis,9,10 the tumor itself clearly ex-
hibits immunoevasive features such as secretion of 
immunomodulatory cytokines, altered expression of 
immunoregulatory receptors, and manipulation of the im-
mune cellular landscape proximal to the tumor.11 One of 
the most clinically relevant questions is how long a glioma 
may reside within the brain before it becomes sympto-
matic, and if and how it may undergo malignant transfor-
mation to higher grade gliomas. This is likely to vary by the 
type of glioma. We believe that part of this process will be 
found to include immunomodulatory manipulations.
This study was designed to evaluate characteristics 
at study entry and immune factors within prediagnostic 
blood samples from the Prostate Lung Colorectal Ovarian 
Cancer (PLCO) Cancer Screening Trial among glioma cases 
and matched controls.12,13 The original aim of the PLCO 
Cancer Screening Trial was to evaluate screening methods 
in stored blood samples for utility in screening for common 
cancers.12,13 The PLCO Cancer Screening Trial was extended 
to include other diseases identified during follow-up,12,13 al-
lowing for evaluation of various immune factors and their 
association with glioma risk at baseline and over time.
Study Population and Methods
Study Population 
The PLCO Cancer Screening Trial was a prospective ran-
domized cancer screening trial with the aim of evaluating 
the utility of X-rays for lung cancer diagnosis, sigmoidos-
copy for colorectal cancer, CA125 for ovarian cancer, and 
Prostate Specific Antigen (PSA) for prostate cancer as 
screening tools (NCT00339495). A total of 154,897 subjects 
between ages 55 and 74 were randomized between 1993 
and 2001 at 10 centers located across the United States 
(Alabama, Colorado, Hawaii, Michigan, Minnesota, 
Missouri, Pennsylvania, Utah, Washington D.C., and 
Wisconsin). All participants provided informed consent and 
completed a self-administered baseline questionnaire.14 
All participants were cancer-free at inclusion and received 
routine care with those in the intervention arm also re-
ceived cancer screening. Participants in the intervention 
arm also provided blood samples at five predefined times 
during the trial and form the basis of the Etiology and Early 
Markers Study (EEMS), an ongoing observational cohort 
with prediagnostic specimens. Follow-up for all partici-
pants lasted until at least 2010. Cancer occurrences were as-
certained by annual mailed questionnaire (>95% follow-up 
rate) and verified through death certificates and medical 
records. Ethical approval was obtained at all PLCO Cancer 
Screening Trial sites. The current study was performed 
on de-identified samples and data from the PLCO Cancer 
Screening Trial, and was approved by IRBs at the University 
of California San Francisco (UCSF), University of Southern 
California (USC), and the National Cancer Institute Special 
Studies Institutional Review Board (NCI-SSIRB).
Nested Case–Control Study 
Only participants in the PLCO intervention arm were used for 
this report because of the availability of blood samples. During 
the follow-up period, newly diagnosed glioma cases were 
identified as those diagnosed with International Classification 
of Diseases for Oncology version 2 (ICD-O-2) site codes: 
C71.0-C71.9. All cases had a histopathological glioma confir-
mation and the glioma diagnosis was the first cancer diag-
nosis for each individual glioma case. A total of 124 glioma 
cases were identified and matched to 496 cancer-free controls 
(1:4 ratio) based on age at enrollment (<60, 60–64, 65–69, ≥70), 
sex, ethnicity, and month of blood draw (2  month groups 
starting at January/February, March/April, etc.).
Exposure Assessment
Demographics, such as weight, height, smoking history, 
cancer history among first-degree relatives, glioma his-
tory among first-degree relatives, diabetes, hypertension, 
Importance of the Study
This nested case–control study within the inter-
vention arm of the Prostate, Lung, Colorectal, 
and Ovarian Cancer (PLCO) Screening Trial rep-
licated that allergen-specific IgE is inversely as-
sociated with glioma risk. This is also the first 
prospective study to show that a family history 
of glioma is associated with increased glioma 
risk, which is consistent with the literature. 
TGF-β1, which was analyzed in prospectively 
collected serum samples, was not associated 
with glioma risk at baseline but became sig-
nificant closer towards diagnosis, which may 
reflect the presence of a tumor before tumor 
diagnosis or manipulation of the immune 
system by the tumor prior to diagnosis. These 
results are indicative of a protracted prod-
romal immune impact of glioma which may be 
capitalized for early detection, prevention, or 
treatment modalities to improve outcomes for 
glioma patients.











comorbidities, and other potential risk factors for glioma, 
were obtained from the baseline questionnaire admin-
istered at study entry. Data on exogenous hormone use, 
parity, age of the first child, and menopausal status were 
collected for female participants. Prostate-related factors 
were also evaluated among male participants. Serum sam-
ples for subjects in our nested case–control study were 
transferred to University of California at San Francisco 
for conducting immune-related measurements, including 
TGF-β1, TNF-α, total IgE, and respiratory allergen-specific 
IgE (Phadiatop: mite, oak, ragweed, grass, dog, cat, and 
Alternaria).15 Immune factors were measured using serum 
samples collected at baseline for all cases and controls. 
Additional repeated serum samples were obtained by 
PLCO staff at years 1, 2, 4, and 5 of follow-up. However, 
only a subset of the repeated serum samples was analyzed, 
with a higher proportion being requested from cases. One 
or more repeated (post-baseline) serum samples were 
obtained for 87% of cases (n = 108) and 15% of controls 
(n  = 72). Immune factors were measured using Luminex 
for the cytokines (Millipore) and Phadia for the two IgE-
related measures. All tests were performed in duplicate 
and in reference to appropriate standard curves. When du-
plicate measurements had a coefficient of variation of over 
20%, the test was redone. Duplicate measures were aver-
aged for analysis.
Statistical Analysis
Height and weight at age 20 and at study entry were de-
termined, and each was categorized based on quartile 
cutpoints in controls for use in statistical models. Body 
mass index (BMI) at age 20 and study entry was calcu-
lated as weight in kg divided by height in m2 and categor-
ized as <25, 25 to <30, and ≥30 kg/m2. Smoking status was 
categorized as never smoker, past smoker, and current 
smoker. IgEs were classified according to clinically ac-
cepted criteria and were categorized as elevated if >100 
kU/mL.16 Respiratory allergen-specific IgE was categor-
ized as elevated if >0.35 PAU/L.10,17 TGF-β1 was categorized 
by quartiles in controls at baseline (with cutpoints 1,027, 
1,284.6, and 1,533.2 pg/mL). TNF-α was categorized by 
quartiles in controls at baseline (with cutpoints 12.4, 16.5, 
and 22.0 pg/mL). Variables that were evaluated by quar-
tiles were also visualized using boxplots by case–control 
status and by measurement year and were created in R 
(version 3.6.0).
The association between evaluated baseline character-
istics and glioma was estimated by odds ratios (ORs) and 
95% confidence intervals (CIs) using conditional logistic 
regression. All models for BMI and weight were adjusted 
for diabetes status and education. Models for smoking 
history were adjusted for diabetes status, education, and 
hypertension, and models for a family history of cancer or 
glioma were adjusted for smoking status. BMI, weight, and 
height were analyzed as categorical variables in all models. 
P-values for trend were calculated for BMI, weight, height, 
and factors that were categorized by quartiles by entering 
the ordinal values representing categories for these factors 
as continuous variables in the models to evaluate trends. 
Conditional logistic regression was performed using the 
“clogistic” function from the Epi package in R.18,19 Immune 
factors were evaluated using a multivariate conditional lo-
gistic regression model with correction for batch number. 
An additional multivariate logistic regression model was 
created, which incorporated measurements from the latest 
available serum sample when available. This model was 
adjusted for age, sex, ethnicity, and month of blood draw 
as matching had to be broken for this analysis.
Results
The baseline characteristics of glioma cases and con-
trols are depicted in Table 1. The mean age at entry was 
63  years (SD  =  5.2). The majority of both cases and 
  
Table 1. Baseline characteristics for the glioma cases and controls for matching variables and days to case–control status
Variable Cases (N = 124) Controls (N = 496) P-value Overall (N = 620)
Sex (N (%))     
 Male 81 (65) 324 (65) >.99 405 (65)
 Female 43 (35) 172 (35)  215 (35)
Ethnicity (N (%))     
 Non-Hispanic White 118 (95) 472 (95) >.99 590 (95)
 Hispanic 1 (1) 4 (1)  5 (1)
 Black non-Hispanic 3 (2) 12 (2)  15 (2)
 Other 2 (2) 8 (2)  10 (2)
Age (years (SD)     
 Mean (SD) 63.5 (±5.0) 63.4 (±5.3) .884 63 (5.2)
Time to disease (cases) or censoring (controls, in years (SD))     
 Mean (SD) 6.5 (3.9) 12.4 (2.6) <.001 11.2 (3.7)
The table depicts the variables that were used to match cases to controls. P-values were calculated using t-test for continuous variables and chi-
squared test for categorical variables.
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controls were male (65%). Non-Hispanic whites were the 
most common ethnicity (95%), followed by non-Hispanic 
blacks (2%), and Hispanics (1%). Observation time for 
cases ended at diagnosis and therefore cases (mean 
6.5  years) were observed for a shorter time than con-
trols (mean 12.4 years, P < .001). Ninety-three out of the 
124 glioma cases were diagnosed with a glioblastoma 
(GBM, 75.0%).
A family history among first-degree relatives of glioma 
was associated with increased glioma risk (OR  =  4.41, 
P = .002, Table 2). A history of any cancer among first-de-
gree relatives was not associated with increased glioma 
risk (P = .18). Increased weight (Q3 with Q1 as reference) 
was associated with increased glioma risk (P  =  .03), but 
the pattern across quartiles was not consistent (trend 
P-value  =  .12). No other anthropometric factor at base-
line was significantly associated with case–control status. 
Smoking status was not associated with glioma risk. No 
comorbidity evaluated at baseline was associated with 
glioma risk (Supplementary Table S1). None of the evalu-
ated factors specific to males and females were associated 
with glioma risk (Supplementary Tables S2 and S3).
Comparison of the distribution of TGF-β1 and TNF-α ap-
pears to indicate that, at later years of measurement, 
higher TGF-β1 is observed among cases compared with 
controls (Figure 1). In multivariate modeling of immune 
factors at baseline, increased respiratory allergen-specific 
IgE was inversely associated with glioma risk (OR for IgE 
> 0.35 PAU/L: 0.59, P = 0.03, Table 3). No significant asso-
ciations were observed for TGF-β1, TNF-α, and total IgE. 
The multivariate logistic regression model that incorpo-
rated the latest available measures also showed that in-
creased respiratory allergen-specific IgE was significantly 
inversely associated with glioma risk (OR for respiratory 
  
Table 2. Associations between anthropometric factors, smoking history, and family history of cancer and glioma among first-degree relatives at 
baseline
Variable Cases Controls OR 95% CI P-value P-value for trend
Low High
BMI (kg/m2)a,b        
 <25 40 151 Ref.    .86
 25 to <30 53 226 1.01 0.59 1.73 .97  
 ≥ 30 29 115 1.06 0.57 1.98 .86  
BMI at age 20 (kg/m2)a        
 <25 93 419 Ref.    .15
 25 to <30 23 62 1.74 0.93 3.24 .08  
 ≥30 3 9 1.10 0.20 6.02 .91  
Weight (kg)a        
 Q1 (<70.6) 26 124 Ref.    .12
 Q2 (≥70.6 to <79.8) 24 123 1.13 0.51 2.48 .76  
 Q3 (≥79.8 to <90.7) 48 133 2.26 1.09 4.69 .03  
 Q4 (≥90.7) 25 116 1.49 0.66 3.35 .34  
Height (cm)        
 Q1 (<165.2) 30 140 Ref.    .09
 Q2 (≥165.2 to <175) 34 125 1.49 0.78 2.84 .22  
 Q3 (≥175 to <182) 26 135 1.19 0.51 2.74 .69  
 Q4 (≥182) 32 92 2.16 0.93 5.02 .07  
Smoking historyc        
Nonsmoker 54 222 Ref.     
 Past smoker 61 240 1.04 0.64 1.68 .88  
 Current smoker 9 34 1.89 0.71 5.01 .20  
Family history of cancerd        
 Family history of cancer 77 275 1.33 0.88 2.00 .18  
Family history of gliomad        
 Family history of glioma 9 8 4.41 1.69 11.47 .002  
Height and weight were evaluated by quartiles among controls. 
aBMI, BMI at age 20, and weight were adjusted for diabetes status and education. 
bCurrent BMI. 
cSmoking history was adjusted for diabetes status, education, and hypertension. 
dFamily history of cancer and glioma were adjusted for smoking status.
Bold values indicate significant P-values (i.e., P < .05). 
  











allergen-specific IgE > 0.35 PAU/L: 0.48, P = .005, Table 4). 
Unlike the baseline model, increased TFG-β1 was associ-
ated with increased glioma risk (OR for TGF-β1: Q4 vs. Q1: 
2.96, P-value for trend: <.0001, Table 4).
Discussion
In this study, glioma cases and matched controls among 
the intervention arm of the EEMS component of the 
PLCO Cancer Screening Trial were evaluated for base-
line characteristics and various immune-related factors 
in prediagnostic blood serum for association with glioma 
case–control status. With regard to baseline character-
istics, this study supported a role for family history of 
glioma among first-degree relatives and increased glioma 
risk but did not demonstrate significant associations with 
various anthropometric factors such as BMI and height. 
We also evaluated various immune factors for associ-
ation with glioma case–control status and showed that 
elevated respiratory allergen-specific IgE was associated 
with decreased risk. This association was also identified 
in a logistic regression model that incorporated the latest 
available measurements to account for updated longitu-
dinal measurements in a portion of the study population. 
The logistic regression that incorporated the latest avail-
able measurements showed that elevated TGF-β1 is associ-
ated with increased glioma risk.
A family history of glioma among first-degree relatives 
has previously been associated with increased glioma 
risk,5–7,20 which is consistent with our study. To the best 
of our knowledge, this is the first prospective cohort 
study to show that a family history of glioma is associ-
ated with increased risk. The result is also unlikely to be 
affected by diagnostic bias, since this history was col-
lected prior to glioma diagnosis among study subjects. 
This finding may be explained by families harboring 
rare putative germline mutations that result in increased 
risk, which is supported by studies that identified rare 
germline variants in glioma predisposing genes among 
such families.21–23 It has even been suggested that family 
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Control Case Control Case Control Case Control Case Control Case
Control Case Control Case Control
Case-control status
Case Control Case Control Case
0
Fig. 1 Boxplots depicting TGF-β1 and TNF-α by case-control status and by measurement year. The boxplots depict the measures of TGF-β1 and 
TNF-α by case–control status for each of the years of measurements (0, 1, 2, 4, and 5). No measurements were taken at year 3. P-values were 
derived from t-tests.
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Table 3. Multivariate conditional logistic regression model for immune factors at baseline for association with glioma
OR 95% CI P-value P-value for trend
Low High
Total IgE (kU/mL)      
 Normal (≤100) Ref.     
 Elevated (>100) 1.06 0.62 1.83 .82  
Respiratory allergen-specific IgE (PAU/L)      
 Normal (≤0.35) Ref.     
 Elevated (>0.35) 0.59 0.37 0.95 .03  
TNF-α (pg/mL)     .56
 Q1 (≤12.4) Ref.     
 Q2 (>12.4 to ≤16.5) 0.89 0.48 1.65 .72  
 Q3 (>16.5 to ≤22.0) 0.95 0.52 1.73 .85  
 Q4 (>22.0) 1.18 0.65 2.15 .59  
TGF-β1 (pg/mL)     .14
 Q1 (≤1,027) Ref.     
 Q2 (>1,027 to ≤1,284.61) 0.98 0.52 1.85 .95  
 Q3 (>1284.61 to ≤1,533.15) 1.60 0.90 2.85 .11  
 Q4 (>1,533.15) 1.36 0.73 2.52 .34  
ORs were stratified by matching set and adjusted for batch number. 
OR = odds ratio; CI = confidence interval.
Bold values indicate significant P-values (i.e., P < .05). 
  
  
Table 4. Multivariate logistic regression model using the latest available measurements for each study participant
Variable OR 95% CI P-value P-value for trend
Low High
Total IgE (kU/mL)      
 Normal (≤100) Ref.     
 Elevated (>100) 0.88 0.48 1.55 .67  
Respiratory allergen-specific IgE (PAU/L)      
 Normal (≤0.35) Ref.     
 Elevated (>0.35) 0.48 0.28 0.97 .005  
TNF-α (pg/mL)     .60
 Q1 (≤12.4) Ref.     
 Q2 (>12.4 to ≤16.5) 1.05 0.56 2.00 .87  
 Q3 (>16.5 to ≤22.0) 1.40 0.76 2.59 .28  
 Q4 (>22.0) 1.07 0.58 2.01 .82  
TGF-β1 (pg/mL)     <.0001
 Q1 (≤1,027) Ref.     
 Q2 (>1,027 to ≤1,284.61) 0.80 0.40 1.55 .50  
 Q3 (>1,284.61 to ≤1,533.15) 1.43 0.76 2.69 .27  
 Q4 (>1,533.15) 2.96 1.68 5.31 .0002  
ORs were stratified by matching set and adjusted for batch number. 
OR = odds ratio; CI = confidence interval.
Bold values indicate significant P-values (i.e., P < .05). 
  











members of a particular family with multiple reported 
gliomas tend to develop gliomas of the same molecular 
subtype.24 Increased height has previously been associ-
ated with increased glioma risk,25,26 but this was not ob-
served in this study.
The negative association between allergen-specific IgE 
and glioma risk has been previously identified,10 but this 
was not significant in another study.27 A reported history of 
atopy has also previously been associated with decreased 
glioma risk.4,8 However, a recent Mendelian randomization 
study only provided weak evidence for an association be-
tween atopy risk and glioma28; hence, the genetic compo-
nent of this risk may be low. Higher prediagnostic total IgE 
has also been associated with decreased glioma risk,10 al-
though one other study did not observe this association.27 
A  meta-analysis using a combination of studies of pre- 
and post-diagnostic sera identified that higher total IgE 
was associated with decreased risk, but that respiratory 
allergen-specific IgE was not,29 which is not in line with 
the findings of the current study as total IgE was not asso-
ciated with glioma case–control status. We were not able 
to assess self-reported allergy as the PLCO cohort had not 
collected data on this factor, but our result is in line with 
other studies that assessed hay fever and other reported 
measures of respiratory allergy as being inversely associ-
ated with glioma.9,30
To the best of our knowledge, this is the first study to 
report an association between prediagnostic serum TGF-
β1 with regard to glioma risk. Our findings indicate that 
increased prediagnostic TGF-β1 may reflect an underlying 
disease process but may also be produced by the systemic 
immune system in response to the glioma. Inhibition of 
TGF-β has been shown to improve glioma survival in a 
mouse model potentially due to inhibition of tumor fil-
tration and restoration of the immune surveillance.31 
TGF-β1 greatly influences the immune system through 
influencing T-cell development, limiting B-cell prolifera-
tion and differentiation, limiting the development of nat-
ural killer cells, and limiting dendritic cell functioning.32–34 
It has been suggested that this immunologic inhibition by 
TGF-β1 is necessary for the creation of tolerance for self- 
and innocuous antigens such as gut bacteria and food and 
TGF-β1 malfunctioning may result in severe autoimmu-
nity.34 Secretion of TGF-β1 by glioma cells may, therefore, 
facilitate an immunotolerant environment necessary for 
cancerous growth. TGF-β may result in T-cell sequestra-
tion in the bone marrow among GBM patients through 
down-regulation of S1P1,35 but it should be noted that 
TGF-β blockade did not result in less T-cell sequestration.35 
Glioma cell line studies have also shown that glioma 
cells produce TGF-β1 for retention of stemness of glioma 
initiating cells (GICs) through an induced expression 
of various genes including Sox2, a stemness gene.36,37 
Furthermore, TGF-β1 has been shown to promote cell mi-
gration and invasiveness in glioma and may be involved 
in angiogenesis.38–40
Although these results have not yet been validated by 
other studies, they may provide a potential roadmap for 
early detection and treatment of prodromal glioma prior 
to clinical symptoms. TGF-β1 and other factors such as 
tumor-secreted exosomes41 and germline mutations3 may 
be used clinically to identify people at high risk for glioma, 
identify cases before symptoms occur, and identify pa-
tients with tumors responsive to anti-TGF-β therapy. While 
targeting the TGF beta pathway is under development and 
has been problematic,42,43 other prediagnostic markers 
certainly need to be discovered for the use of high-quality 
prediagnostic cohorts may help facilitate developments in 
preclinical prevention of a deadly disease that has resisted 
clinical breakthroughs for decades.
Strengths and Limitations
This study has various strengths and limitations. The study’s 
primary strengths are the availability of prediagnostic serum 
samples, prospective nature, relatively large sample size, 
and long duration of follow-up. Although the longitudinal 
samples are helpful, one of the limitations is incomplete-
ness of analyzed repeated serum samples in the logistic 
regression model that incorporated the latest available 
measurements which were the result of selection consid-
erations. Estimates may, therefore, be less precise because 
of the incompleteness of the follow-up measures. The use 
of completely cancer-free controls may also have been too 
restrictive. Cases were relatively oversampled for repeated 
measures compared with controls, but we believe that this 
has not introduced bias as the selection of cases and con-
trols and the selection of serum samples was not based on 
any criteria other than availability for cases. At 75%, GBM 
was a more common diagnosis than would be expected in 
the general population44 probably due to the age of inclusion 
of the PCLO Cancer Screening Trial. Another limitation is that 
TGF-β1 was the only TGF isoform to be evaluated.
In conclusion, this study suggests that certain lifetime 
immune-related factors may be associated with glioma risk 
long before diagnosis such as respiratory allergen-specific 
IgE. This study also shows that TGF-β1 becomes associated 
with glioma risk closer towards diagnosis which may reflect 
the underlying disease process. Further evaluation in other 
and larger glioma cohorts with access to prediagnostic blood 
samples are needed to confirm these associations and to eval-
uate potential clinical utility as a diagnostic or screening tool.
Supplementary Material
Supplementary material is available at Neuro-Oncology 
Advances online.
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